FMT May Boost Immunotherapy Effectiveness

Fecal microbiota transplantation may enhance the effectiveness of immunotherapies by reducing gut dysbiosis, ...

AUGUST 25, 2025

Microbiota-Based Therapy for the Prevention of Recurrent Clostridioides difficile Infection:
A Primer on REBYOTA^®
(fecal microbiota, live-jslm)

This Special Report outlines the challenges of treating Clostridioides difficile infection (CDI) and preventing ...

AUGUST 29, 2023

Restoring the Full Diversity of the Gut Microbiome: Can It Break the Cycle of Recurrent C. Difficile Infection?

This Special Report provides a general overview of the role of the gut microbiome, the consequences of its ...

MAY 2, 2022

Studies ID Predictors of FMT Failure, Infection Recurrence in Patients With CDI

Researchers have identified a number of risk factors for treatment failure after fecal microbiota transplantation ...

SEPTEMBER 8, 2021

Microbiome-Based Therapy: The Next Frontier in the Management of Clostridioides difficile Infections and Recurrence

This Special Report describes the gut microbiome, the burden of Clostridioides difficile infection (CDI) and ...

JANUARY 12, 2021

AGA Registry Analysis Confirms Utility of FMT for Recurrent C. difficile

Initial findings from the American Gastroenterological Association Fecal Microbiota Transplantation National ...

DECEMBER 16, 2020

FDA Fast-Tracks FMT Product for C. difficile

The FDA awarded a fast track designation for CP101, an encapsulated, oral fecal microbiota transplant product by ...

APRIL 2, 2018

New C. difficile Guidelines Recommend New Treatment, Testing Protocols

CDI affects nearly 500,000 Americans every year, resulting in 15,000 to 30,000 deaths and costing more than $4.8 ...

FEBRUARY 15, 2018